On June 5, Hyperliquid Strategies fell 8.85% in regular trading, trading at $8.685 USD/share, with trading volume of $61.82 million.
Within the Biotechnology sector where Hyperliquid Strategies belongs, among individual stocks, AbbVie up 1.34%, Amgen up 2.41%, Gilead Sciences up 0.07%, Argenx SE up 3.56%, BioCardia up 53.97%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)